Gilead Sciences, Inc. On A Roll Even Before Breakthrough Hepatitis C Drug's Effects
Gilead Sciences announced financial gains for the fourth quarter and full year of 2013 on Tuesday, even though the Foster City company's latest blockbuster drug debuted just a month before the end of the year, signaling even more gains ahead.
Gilead announced fourth-quarter profits of $791.4 million, or 47 cents a share, on revenues of $3.12 billion, with net income gaining 3.8 percent and revenues jumping 21 percent from the same quarter a year ago. For the full year, Gilead posted gains from 2012 of 15 percent in revenues and 18.5 percent in profits to net income of $3.07 billion on revenues of $11.2 billion.
Help employers find you! Check out all the jobs and post your resume.